Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Xencor Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Xencor Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 08 Dec 2022 | Lorem |
| Xencor, ImmunoGen, MacroGenics’ CD123 antibodies for AML have potential for combinations, experts say; ASH monotherapy early results were less encouraging | 17 Dec 2018 | Mariana Lenharo |
| Xencor reassesses XmAB5871 design for Phase III IgG4-RD study after SLE failure; YE18 target start, CMO says | 26 Oct 2018 | Krystnell Storr |
| Xencor’s XmAb5871 receives tepid response to Phase II lupus study; trial design a catch-22 for short and long-term efficacy, experts say | 30 Aug 2018 | Krystnell Storr |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer